Price: $66.29
· 1 day: -0.10% · 5 days: -1.03% · 1 month: -1.99% · YTD: -2.81%
As of 2026-10-08 18:57 UTC.
52-week range: $61.0 – $85.03 (currently at 22% of the range).
The read
GSKH is in a downtrend, momentum soft. $68.97 is the level overhead; $61.55 the first support below.
6 of 6 technical checks lean bearish.
Price vs 50-day: below
Price vs 200-day: below
50d vs 200d avg: below
MACD: bearish
RSI momentum: 16
5-day tape: -1.0%
Trend
Downtrend · below 50-day & below 200-day
Momentum
RSI 15.72 · neutral · MACD bearish
Trend strength
ADX 14.9 · weak or range
Location
-5.3% vs 50-day MA
52-week range
-22% from high · +8% from low
Volatility
ATR 0.75 · ~1.1%/day
Key levels
Level
Type
Distance
$68.97 (resistance)
swing zone
4.05%
$69.97 (resistance)
sma 50
5.56%
$71.48 (resistance)
swing zone
7.84%
$61.55 (support)
52w low
-7.14%
$60.0 (support)
round
-9.48%
$50.0 (support)
round
-24.57%
Indicators
RSI (14)
15.72
MACD
-1.0715
ADX (14)
14.9
ATR (14)
0.75
50-day average
$69.97
200-day average
$73.2
Latest GSKH news
Halozyme Announces Appointment of Jim Daly to its Board of Directors — Halozyme Therapeutics announced the appointment of James Daly to its Board of Directors on September 30, 2026. Daly is a biopharmaceutical executive with over three decades of commercial leadership experience, previously (PR Newswire, 2026-09-30)
Sysco Draws Blowout Demand for $17 Billion Global Bond Offering — Sysco Corp. attracted approximately $90 billion in orders for the US dollar tranche of its $17 billion global bond offering, with total investor demand reaching roughly $69 billion across the seven-tranche investment-gra (Bloomberg Business, 2026-09-22)
Pharma Bosses Warn European Leaders Future Investment at Risk — European pharmaceutical executives are intensifying pressure on regional governments to increase investment in new medicines, warning that failure to do so could drive future investment to China and the US. Drugmakers ha (Bloomberg Business, 2026-09-22)
Companies Avoid Selling The Bonds Investors Crave — Investors are demonstrating strong demand for long-term corporate bonds, with companies receiving significantly oversubscribed orders despite their reluctance to issue such debt. Aon Inc. received $10 billion in orders f (Bloomberg Business, 2026-09-19)